Neutrophil Gelatinase-Associated Lipocalin in Acute Kidney Injury

Advances in Clinical Chemistry

Volumn 58, Issue , 2012, Pages 141-191

  Makris, Konstantinos ^a   Kafkas, Nikolaos ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862538742     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394383-5.00012-6     Document Type: Chapter

References (193)

1. Xue J.L., Daniels F., Star R.A., et al. Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J. Am. Soc. Nephrol. 2005, 17:1135-1142.
2. Hoste E.A., Schurgers M. Epidemiology of acute kidney injury: how big is the problem?. Crit. Care Med. 2008, 36:S146-S151.
3. Chertow G.M., Burdick E., Honour M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 2005, 16:3365-3370.
4. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. J. Am. Med. Assoc. 2005, 294:813-818.
5. Uchino S., Bellomo R., Goldsmith D., et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit. Care Med. 2006, 34:1913-1917.
6. Bragsaw S.M., George C., Bellomo R., et al. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit. Care 2007, 11:R68-R76.
7. Nash K., Hafeez A., Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 2002, 39:930-936.
8. Kohli H.S., Bhaskaran M.C., Muthukumar T., et al. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol. Dial. Transplant. 2000, 15:212-217.
9. Baraldi A., Ballestri M., Rapana R., et al. Acute renal failure of medical type in an elderly population. Nephrol. Dial. Transplant. 1998, 13(Suppl. 7):S25-S29.
10. Lameire N., Matthys E., Vanholder R., et al. Causes and prognosis of acute renal failure in elderly patients. Nephrol. Dial. Transplant. 1987, 2:316-322.
11. Bonventre J.V. Molecular and genetic aspects of ischemic acute kidney injury. Molecular and Genetic Basis of Renal Disease: A Companion to Brenner and Rector's The Kidney 2008, 531-555. Saunders Publishers, Philadelphia, PA. D.B. Mount, M. Pollack (Eds.).
12. Lameire N., Van Biesen W., Vanholder R. Acute renal failure. Lancet 2005, 365:417-430.
13. Bonventre J.V., Weinberg J.M. Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. 2003, 14:2199-2210.
14. Lattanzio A.R., Kopyt N.P. Acute kidney injury: new concepts in definition, diagnosis, pathophysiology and treatment. J. Am. Osteopathic Ass. 2007, 109:13-19.
15. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 2004, 8:R204-R212.
16. Hou S.H., Bushinsky D.A., Wish J.B., Cohen J.J., Harrington J.T. Hospital-acquired renal insufficiency: a prospective study. Am. J. Med. 1983, 74:243-248.
17. Espinel C.H. The FENa test. Use in the differential diagnosis of acute renal failure. JAMA 1976, 236:579-581.
18. Miller T.R., Anderson R.J., Linas S.L., et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann. Intern. Med. 1978, 89:47-50.
19. Espinel C.H., Gregory A.W. Differential diagnosis of acute renal failure. Clin. Nephrol. 1980, 13:73-77.
20. Zarich S., Fang L.S., Diamond J.R. Fractional excretion of sodium. Exceptions to its diagnostic value. Arch. Intern. Med. 1985, 145:108-112.
21. Pru C., Kjellstrand C.M. The FENa test is of no prognostic value in acute renal failure. Nephron 1984, 36:20-23.
22. Carvounis C.P., Nisar S., Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 2002, 62:2223-2229.
23. Kaplan A.A., Kohn O.F. Fractional excretion of urea as a guide to renal dysfunction. Am. J. Nephrol. 1992, 12:49-54.
24. Van Biesen W., Yegenaga I., Vanholder R., et al. Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J. Nephrol. 2005, 18:54-60.
25. Bagshaw S.M., Langenberg C., Bellomo R. Urinary biochemistry and microscopy in septic acute renal failure-a systematic review. Am. J. Kidney Dis. 2006, 48:695-705.
26. Kanbay M., Kesaoglou B., Perazella M.A. Acute tubular necrosis and prerenal acute kidney injury: utility of urine microscopy in their evaluation-a systematic review. Int. Urol. Nephrol. 2010, 42(2):425-433.
27. Lameire N., Hoste E. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr. Opin. Crit. Care 2004, 10:468-475.
28. Ohkawa S., Odamaki M., Ikegaya N., Hibi I., Miyaji K., Kumagai H. Association of age with muscle mass, fat mass, and fat distribution in non-diabetic hemodialysis patients. Nephrol. Dial. Transplant. 2005, 20:945-951.
29. Hirsh S. Prerenal success in chronic kidney disease. Am. J. Med. 2007, 120:754-759.
30. Martin J.E., Sheaff M.T. Renal ageing. J. Pathol. 2007, 211:198-205.
31. Kellum J.A., Levin N., Bouman C., Lameire N. Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care 2002, 8:509-514.
32. American Society of Nephrology American Society of Nephrology renal Research Report. J. Am. Soc. Nephrol. 2005, 16:1886-1903.
33. Acute dialysis quality initiative group. http://www.adqi.net.
34. Ricci Z., Cruz D., Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008, 73:538-546.
35. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11:R31.
36. Soni S.S., Ronco C., Katz N., Cruz D.N. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif. 2009, 28:165-174.
37. Moran S.M., Myers B.D. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985, 27:928-937.
38. Star R.A. Treatment of acute renal failure. Kidney Int. 1998, 54:1817-1831.
39. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
40. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93:1054-1061.
41. Hewitt S.M., Dear J., Star R.A. Discovery of protein biomarkers for renal disease. J. Am. Soc. Nephrol. 2004, 15:1677-1689.
42. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 2006, 17:1503-1520.
43. Devarajan P., Mishra J., Supavekin S., et al. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol. Genet. Metab. 2003, 80:365-376.
44. Kjeldsen L., Johnsen A.H., Sengelov H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268:10425-10432.
45. Cowland J.B., Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997, 45:17-23.
46. Xu S.Y., Carlson M., Engström A., Garcia R., Peterson C.G., Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand. J. Clin. Lab. Invest. 1994, 54(5):365-376.
47. Friedl A., Stoesz S.P., Buckley P., Gould M.N. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem. J. 1999, 31:433-441.
48. Nielsen B.S., Borregaard N., Bundgaard J.R., Timshel S., Sehested M., Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996, 38:414-420.
49. Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., Gould M.N. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Cancer 1998, 79:565-572.
50. Monier F., Surla A., Guillot M., Morel F. Gelatinase isoforms in urine from bladder cancer patients. Clin. Chim. Acta 2000, 299:11-23.
51. Goetz D.H., Holmes M.A., Borregaard N., et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 2002, 10:1033-1043.
52. Devireddy L.R., Gazin C., Zhu X., Green M.R. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005, 123(7):1293-1305.
53. Goetz D.H., Willie S.T., Armen R.S., et al. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000, 39(8):1935-1941.
54. Schmidt-Ott K.M., Mori K., Li J.Y., et al. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007, 18:407-413.
55. Flo T.H., Smith K.D., Sato S., et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron. Nature 2004, 432:917-921.
56. Berger T., Togawa A., Duncan G.S., et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1834-1839.
57. Yang J., Goetz D., Li J.Y., et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell 2002, 10:1045-1056.
58. Yang J., Blum A., Novak T., Levinson R., Lai E., Barasch J. An epithelial precursor is regulated by the ureteric bud and by the renal stroma. Dev. Biol. 2002, 246:296-310.
59. Meldrum K.K., Hilw K., Meldrum D.R., et al. Simulated ischemia induced renal tubular cell apoptosis through a nuclear factor-κB dependent mechanism. J. Urol. 2002, 168:248-252.
60. Haussler U., von Wichert G., Schmid R.M., et al. Epidermal growth factor activates nuclear factor-κB in human proximal tubule cells. Am. J. Physiol. Renal Physiol. 2005, 280:F808-F815.
61. Mishra J., Mori K., Ma Q., et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase associated lipocalin. J. Am. Soc. Nephrol. 2004, 15:3073-3082.
62. Lim R., Ahmed N., Borregaard N., Riley C., Wafai R., Thompson E.W., Quinn M.A., Rice G.E. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer 2007, 120(11):2426-2434.
63. Bauer M., Eickhoff J., Gould M., Mundhenke C., Maass N., Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res. Treat. 2008, 108:389-397.
64. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 2007, 5(B):463-470.
65. Tong Z., Kunnumakkara A.B., Wang H., et al. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008, 68:6100-6109.
66. Arlinghaus R., Leng X. Requirement of lipocalin 2 for chronic myeloid leukemia. Leuk. Lymphoma 2008, 49(4):600-603.
67. Leng X., Lin H., Ding T., et al. Lipocalin 2 is required for BCR-ABL induced tumorigenesis. Oncogene 2008, 27(47):6110-6119.
68. Devireddy L.R., Teodoro J.G., Richard F.A., Green M.R. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001, 293(5531):829-834.
69. Miharada K., Hiroyama T., Sudo K., et al. Lipocalin 2 functions as a negative regulator of red blood cell production in an autocrine fashion. FASEB J. 2005, 19(13):1881-1883.
70. Miharada K., Hiroyama T., Sudo K., et al. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells. J. Cell. Physiol. 2008, 215(2):526-537.
71. Bolignano D., Coppolino G., Donato V., Lacquaniti A., Bono C., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?. Med. Sci. Monit. 2010, 16(6):RA131-RA135.
72. Xu S., Venge P. Lipocalins as biochemical markers of disease. Biochim. Biophys. Acta 2000, 1482(1-2):298-307.
73. Zerega B., Cermelli S., Michelis B., et al. Expression of NRL/NGAL (neurelated lipocalin/neutrophil gelatinase-associated lipocalin) during mammalian embryonic development and in inflammation. Eur. J. Cell Biol. 2000, 79(3):165-172.
74. Nielsen B.S., Borregaard N., Bundgaard J.R., et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996, 38(3):414-420.
75. Lawrance I.C., Fiocchi C., Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum. Mol. Genet. 2001, 10(5):445-456.
76. Ohlsson S., Wieslander J., Segelmark M. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin. Exp. Immunol. 2003, 131(3):528-535.
77. Brunner H.I., Mueller M., Rutherford C., et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2006, 54(8):2577-2584.
78. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4(2):337-344.
79. Bolignano D., Coppolino G., Romeo A., et al. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol. Dial. Transplant. 2009, 24(11):3398-3403.
80. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
81. Van der Wal A.C., Becker A.E., Van der Loos C.M., et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
82. Ott I., Neumann F.J., Gawaz M., et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996, 94:1239-1246.
83. Jaremo P., Hansson G., Nilsson O. Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST elevation. Thromb. Res. 2000, 100:471-478.
84. Buffon A., Biasucci L.M., Liuzzo G., et al. Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 2002, 347:5-12.
85. Patel P.B., Pfau S.E., Cleman M.W., et al. Comparison of coronary artery specific leukocyte-platelet conjugate formation in unstable versus stable angina pectoris. Am. J. Cardiol. 2004, 93:410-413.
86. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106:2894-2900.
87. Madjid M., Awan I., Willerson J.T., et al. Leukocyte count and coronary heart disease: implications for risk assessment. J. Am. Coll. Cardiol. 2004, 44:1945-1956.
88. Sarndahl E., Bergstrom I., Brodin V.P. Neutrophil activation status in stable coronary artery disease. PLoS One 2007, 2:e1056. 10.1371/journal.pone.0001056.
89. Goldmann B.U., Rudolph V., Rudolph T.K., et al. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic. Biol. Med. 2009, 47:79-83.
90. Elneihoum A.M., Falke P., Hedblad B., et al. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997, 131:79-84.
91. Elneihoum A.M., Falke P., Axelsson L., et al. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996, 27:1734-1738.
92. Falke P., Elneihoum A.M., Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc. Dis. 2000, 10:97-101.
93. Hemdahl A.L., Gabrielsen A., Zhu C., et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2006, 26:136-142.
94. Folkesson M., Kazi M., Zhu C., et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurisms. Thromb. Haemost. 2007, 98:427-433.
95. Galis Z.S., Sukhova G.K., Lark M.V., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
96. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteinase-2 and-9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 1998, 32:368-372.
97. Leclerq A., Houard X., Phillippe M., et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J. Leukoc. Biol. 2007, 82:1420-1429.
98. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 1999, 147:213-215.
99. Choi K.M., Lee J.S., Kim E.J., et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol. 2008, 158:203-207.
100. Zographos T., Haliassos A., Korovessis S., et al. Association of netrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am. J. Cradiol. 2009, 104:917-920.
101. Yndestad A., Landro L., Ueland T., et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur. Heart J. 2009, 30:1229-1236.
102. Kjeldsen L., Bainton D.F., Sengelov H., Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994, 83:799-807.
103. Wang Y., Lam K.S., Kraegen E.W., et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 2007, 53:34-41.
104. Yan Q.W., Yang Q., Mody N., et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007, 56:2533-2540.
105. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney Dis. 2008, 52:595-609.
106. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003, 14:2534-2543.
107. Nickolas T.L., O'Rourke M.J., Yang J., et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern. Med. 2008, 148:810-819.
108. Dent C.L., Ma Q., Dastrala S., et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit. Care 2007, 11:R127. 10.1186/cc6192.
109. Bennett M., Dent C.L., Ma Q., et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 2008, 3:665-673.
110. Grenier F.C., Ali S., Syed H., et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin. Biochem. 2010, 43:615-620.
111. Haase-Fielitz A., Haase M., Bellomo R. Instability of urinary NGAL during long-term storage. Am. J. Kidney Dis. 2009, 53:564-565.
112. Cai L.J., Borowiec J., Xu S.Y., Han W.Y., Venge P. Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin. Chim. Acta 2009, 403:121-125.
113. James S., Flodin M., Johnston N., Lindahl B., Venge P. The antibody configurations of cardiac troponin I assays may determine their clinical performance. Clin. Chem. 2006, 52:832-837.
114. Cai L., Rubin J., Han W., Venge P., Xu S.Y. The origin of multiple molecular forms in urine of HNL/NGAL. Clin. J. Am. Soc. Nephrol. 2010, 5:2229-2235.
115. Xu S.Y., Peterson C.G., Carlson M., Venge P. The development of an assay for human neutrophil lipocalin (HNL) to be used as a specific marker of neutrophil activity in vivo and vitro. J. Immunol. Methods 1994, 171:245-252.
116. Delanaye P., Rozet E., Krzesinski J.M., Cavalier E. Urinary NGAL measurement: biological variation and ratio to creatinine. Clin. Chim. Acta 2011, 412:390.
117. Waikar S.S., Sabbisetti V.S., Bonventre J.V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010, 78:486-494.
118. Sutton T.A., Molitoris B.A. Mechanisms of cellular injury in ischemic acute renal failure. Semin. Nephrol. 1998, 18:490-497.
119. Sheridan A.M., Bonventre J.V. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr. Opin. Nephrol. Hypertens. 2000, 9:327-334.
120. Supavekin S., Zhang W., Kucherlapati R., Kaskel F.J., Moore L.C., Devarajan P. Differential gene expression following early renal ischemia-reperfusion. Kidney Int. 2003, 63:1714-1724.
121. Yang J., Goetz D., Li J.-Y., Wand W., Mori K., Setlik D., Du T., Erdjument-Bromage H., Tempst P., Strong R., Barasch J. An iron delivery pathway mediated by a lipocalin. Mol. Cell 2002, 10:1045-1056.
122. Yang J., Mori K., Li J.Y., Barasch J. Iron, lipocalin, and kidney epithelia. Am. J. Physiol. Renal Physiol. 2003, 285:F9-F18.
123. Grigoryev D.N., Liu M., Hassoun H.T., et al. The local and systemic inflammatory transcriptome after acute kidney injury. J. Am. Soc. Nephrol. 2008, 19:547-558.
124. Mori K., Lee H.T., Rapoport D., et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 2005, 115:610-621.
125. Ma Q., Devarajan P. Induction of proapoptotic Daxx following ischemic acute kidney injury. Kidney Int. 2008, 74:310-318.
126. Srichai M.B., Hao C., Davis L., et al. Apoptosis of the thick ascending limb results in acute kidney injury. J. Am. Soc. Nephrol. 2008, 19:1538-1546.
127. Mishra J., Mori K., Ma Q., et al. Neutrophil gelatinase-associated lipocalin (NGAL): a novel urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 2004, 24:307-315.
128. Chertow G.M., Levy E.M., Hammermeister K.E., Grover F., Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am. J. Med. 1998, 104:343-348.
129. Lassnigg A., Schmidlin D., Mouhieddine M., et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J. Am. Soc. Nephrol. 2004, 15:1597-1605.
130. Loef B.G., Epema A.H., Smilde T.D., et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J. Am. Soc. Nephrol. 2005, 16:195-200.
131. Bellomo R., Auriemma S., Fabbri A., et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int. J. Artif. Organs 2008, 31(2):166-178.
132. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury following cardiac surgery. Lancet 2005, 365:1231-1238.
133. Parikh C.R., Mishra J., Thiessen-Philbrook H., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006, 70:199-203.
134. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008, 73:465-472.
135. Wagener G., Jan M., Kim M., et al. Association between increases in urinary neutrophil-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006, 105:485-491.
136. Koyner J., Bennett M., Worcester E., et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008, 74(8):1059-1069.
137. Wagener G., Gubitosa G., Wang S., et al. Urinary neutrophil-associated lipocalin and acute kidney injury after cardiac surgery. Am. J. Kidney Dis. 2008, 52(3):425-433.
138. Xin C., Yulong X., Yu C., et al. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren. Fail. 2008, 30:904-913.
139. Tuladhar S.M., Puntmann V.O., Soni M., et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J. Cardiovasc. Pharmacol. 2009, 53:261-266.
140. Haase-Fielitz A., Bellomo R., Devarajan P., et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery-a prospective cohort study. Crit. Care Med. 2009, 37(2):553-560.
141. Haase M., Bellomo R., Devarajan P., et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann. Thorac. Surg. 2009, 88(1):124-130.
142. Haase-Fielitz A., Bellomo R., Devarajan P., et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol. Dial. Transplant. 2009, 24(11):3349-3354.
143. Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am. J. Kidney Dis. 2008, 52:395-399.
144. McIlroy D.R., Wagener G., Lee H.T. Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin. J. Am. Soc. Nephrol. 2010, 5(2):211-219.
145. Haase M., Bellomo R., Devarajan P., et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009, 54(6):1012-1024.
146. Perico N., Cattaneo D., Sayegh M.H., Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004, 364:1814-1827.
147. Halloran P.F., Hunsicker L.G. Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am. J. Transplant. 2001, 1:115-120.
148. Mishra J., Ma Q., Kelly C., et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr. Nephrol. 2006, 21:856-863.
149. Parikh C.R., Jani A., Mishra J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 2006, 6:1639-1645.
150. Hall I.E., Yarlagadda S.G., Coca S.G., et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J. Am. Soc. Nephrol. 2010, 21(1):189-197.
151. Kusaka M., Kuroyanagi Y., Mori T., et al. Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant. 2008, 17:129-134.
152. Pannu N., Wiebe N., Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006, 295:2765-2779.
153. Katzberg R.W., Morris T.W., Burgener F.A. Renal renin and hemodynamic responses to selective renal artery catheterization and angiography. Invest. Radiol. 1977, 12381-12388.
154. Solomon R. Contrast media nephropathy-how to diagnose and how to prevent?. Nephrol. Dial. Transplant. 2007, 22(7):1812-1815.
155. McCullough P.A. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 2008, 51:1419-1428.
156. Fishbane S., Durham J.H., Marzo K., Rundnik M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J. Am. Soc. Nephrol. 2004, 15:251-260.
157. Bachorzewska-Gajewska H., Malyszko J., Sitniewska E., et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am. J. Nephrol. 2006, 26:287-292.
158. Bachorzewska-Gajewska H., Malyszko J., Sitniewska E., et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol. Dial. Transplant. 2007, 22:295-296.
159. Ling W., Zhaohui N., Ben H., et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin. Pract. 2008, 108:c176-c181.
160. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294(7):813-818.
161. Joannidis M., Metnitz B., Bauer P., et al. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med. 2009, 35(10):1692-1702.
162. Guerin C., Girard R., Selli J.M. Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Am. J. Respir. Crit. Care Med. 2000, 161:872-879.
163. Bagshaw S.M., George C., Bellomo R., for the ANZICS Database Management Committee Early acute kidney injury and sepsis: a multicentre evaluation. Crit. Care 2008, 12:R47-R55.
164. Zappitelli M., Washburn K.M., Arikan A.A., et al. Urine NGAL is an early marker of acute kidney injury in critically ill children. Crit. Care 2007, 11:R84.
165. Wheeler D.S., Devarajan P., Ma Q., et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit. Care Med. 2008, 36:1297-1303.
166. Makris K., Markou N., Evodia E., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin. Chem. Lab. Med. 2009, 47(1):79-82.
167. Siew E.D., Ware L.B., Gebretsadik T., et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J. Am. Soc. Nephrol. 2009, 20(8):1823-1832.
168. Cruz D.N., de Cal M., Garzotto F., et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 2009, 36(3):444-451.
169. Bagshaw S.M., Bennett M., Haase M., et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2009, 36(3):452-461.
170. Constantin J.M., Futier E., Perbet S., et al. Plasma neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in adult critically ill patients: a prospective study. J. Crit. Care 2009, 25:e1-e6.
171. Niemann C.U., Walia A., Waldman J., et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 2009, 15:1852-1860.
172. Shapiro N.I., Trzeciak S., Hollander J.E., et al. A prospective multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock and death in emergency department patients with suspected sepsis. Crit. Care Med. 2009, 37:96-104.
173. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
174. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. 2006, 47:1987-1996.
175. Coresh J., Astor B.C., Greene T., Eknoyan G., Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003, 41:1-12.
176. Bock J.S., Gottlieb S.S. Cardiorenal syndrome: new perspectives. Circulation 2010, 121:2592-2600.
177. Ronco C., McCullough P., Anker S.D., et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 2010, 31:703-711.
178. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J. Card. Fail. 2002, 8:136-141.
179. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 2004, 43:61-67.
180. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S1-S266.
181. Heywood J.T., Fonarow G.C., Costanzo M.R., Mathur V.S., Wignesw-aran J.R., Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J. Card. Fail. 2007, 13:422-430.
182. Tonelli M., Wiebe N., Culleton B., et al. Chronic kidney disease and mortality risk: a systematic review. J. Am. Soc. Nephrol. 2006, 17:2034-2047.
183. Alvelos M., Pimentel R., Pinho E., et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type-1 cardio-renal syndrome in the general ward. Clin. J. Am. Soc. Nephrol. 2011, 6(3):476-481.
184. Kent D.M., Jafar T.H., Hayward R.A., et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J. Am. Soc. Nephrol. 2007, 18:1959-1965.
185. Hunsicker L.G., Adler S., Caggiula A., et al. Predictors of the progression of renal disease in the modification of diet in Renal Disease Study. Kidney Int. 1997, 51:1908-1919.
186. Eddy A.A., Neilson E.G. Chronic kidney disease progression. J. Am. Soc. Nephrol. 2006, 17:2964-2966.
187. Bolignano D., Coppolino G., Campo S., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol. Dial. Transplant. 2008, 23:414-416.
188. Bolignano D., Coppolino G., Lacquaniti A., et al. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin (NGAL) in macroproteinuric patients with worsening renal function. Kidney Blood Press. Res. 2008, 31:274-279.
189. Bolignano D., Coppolino G., Aloisi C., et al. Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase associated lipocalin levels in proteinuric patients with normal renal failure. J. Investig. Med. 2008, 31:255-258.
190. Boldt J., Brosch C., Ducke M., et al. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit. Care Med. 2007, 35:2740-2746.
191. Boldt J., Brosch C.H., Rohm K., et al. Comparison of the effects of gelatin and a modern hydroxyethylstarch solution on renal function and inflammatory response in elderly cardiac surgery patients. Br. J. Anaesth. 2008, 100:457-464.
192. Boldt J., Suttner S., Brosch C., et al. Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy. Anesth. Analg. 2009, 109(6):1752-1762.
193. Trachtman H., Christen E., Cnaan A., et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr. Nephrol. 2006, 21:989-994.